CEO Richard Clark

Amylin Pharmaceuticals Inc. (AMLN) (AMLN), the diabetes drugmaker that has put itself up for sale, received offers from Sanofi (SAN) and Merck & Co. in an initial round of bidding, said three people familiar with the process. The companies made bids of at least $25 a share, said the people, who declined to be identified as the deliberations are private. That would value Amylin at more than $4 billion...  

Merck & Co. CEO Kenneth Frazier tells company shareholders that this year and next will be difficult. Speaking at the companys annual meeting, Frazier noted the drugmakers top-selling product, asthma and allergy drug Singulair, gets U.S. generic competition soon. That will sharply reduce revenue from Singulair, which brought in $5.5 billion last year. He also cited an uncertain global economy. But...  

Amylin Pharmaceuticals Inc. (AMLN), the diabetes drugmaker that has put itself up for sale, received offers from Sanofi (SAN) and Merck & Co. in an initial round of bidding, said three people familiar with the process. The companies made bids of ...  

A follow-up study on an AIDS vaccine trial that had to be stopped early has confirmed the worst fears of researchers: The vaccine made it more likely, not less, that some men would become infected with H.I.V. Men who were not circumcised and who had previously caught common colds caused by the same virus used to make the vaccine were two to four times as likely as other men to become infected if they...  

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--At their meeting today, the Board of Directors of Merck & Co., Inc. declared a quarterly dividend of $0.42 per share on the company’s common stock for the third quarter of 2012. Payment will be made on July 9, 2012 to stockholders of record at the close of business on June 15, 2012. About Merck Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside...  

Amylin Pharmaceuticals Inc., the diabetes drugmaker that’s up for sale, has received first-round bids from Sanofi and Merck & Co., said three people familiar with the process. The companies made offers of at least $25 a share, said the people ...  

BRIDGEWATER, N.J. (AP) - Merck & Co. CEO Kenneth Frazier tells company shareholders that this year and next will be difficult. Speaking at the company's annual meeting, Frazier noted the drugmaker's top-selling product, asthma and allergy drug Singulair ...  

Merck & Co. (MRK) isnt liable in Australia for heart risks associated with the Vioxx painkiller, the countrys top court ruled, upholding an appeal of the first trial decision outside the U.S. Graeme Robert Peterson was awarded A$287,912 ($290,000) in a 2010 ruling that found Vioxx contributed to his heart attack in 2003, and a Federal Court appeal panel in Melbourne reversed that decision in October...  

AUGUSTA - Attorney General William J. Schneider announced today that Maine has received payment of more than $1.1 million in a nationwide settlement with pharmaceutical manufacturer Merck Sharp & Dohme Corp. (Merck) involving allegations of off-label marketing and failure to disclose potential adverse health effects of the painkiller Vioxx.The settlement agreement, reached with the United States and 43 states and the District of Columbia in...  

(AP) BRIDGEWATER, N.J. - Merck & Co. (MRK) CEO Kenneth Frazier tells company shareholders that this year and next will be difficult. Speaking at the company's annual meeting, Frazier noted the drugmaker's top-selling product, asthma and allergy ...  

Merck & Co. (MRK) isn’t liable in Australia for heart risks associated with the Vioxx painkiller, the country’s top court ruled, upholding an appeal of the first trial decision outside the U.S. Merck withdrew Vioxx in 2004 after a study ...  

USA TODAYMERCK & CO., INC. : WSJ UPDATE : Merck Anticlotting Drug Shows Benefit And ...4-tradersBy Ron Winslow and Peter Loftus Merck & Co.'s (MRK) experimental anticlotting drug vorapaxar proved effective in preventing heart attacks and other events for patients with heart disease in a major study, but the price was a sharp increase in the risk ...Merck ponders next step for troubled heart drugBusinessWeekMerck Anticlotting Drug Shows Benefit...  

Pro Bono Partnership Honors Merck and Jackson LewisCitybizlist (press release)These outstanding volunteers were recognized at a March 22 reception hosted by Hogan Lovells at Hogan's Manhattan office: Merck & Co.; Jackson Lewis; and attorneys Patricia A. Bowen, UnitedHealthcare Employer & Individual; Melanie L. Brown, BASF; ...  

Merck to take more time with blood thinnerHerald and NewsCHICAGO (AP) — Officials at drugmaker Merck & Co. say they will take more time to decide what to do about an experimental blood thinner that gave disappointing results in a second big study. The study was aimed at preventing repeat heart attacks and ...and more »  

Merck blood clot drug in limbo after mixed resultsBaltimore SunCHICAGO (Reuters) - Impressive efficacy but worrisome bleeding was seen for a new type of blood clot preventer tested by Merck & Co in one of the largest heart-drug studies ever conducted, raising questions whether the company will seek approval of the ...